Inspire Advisors’s ImmunityBio IBRX Stock Holding History

Inspire Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-63	Closed	-$1K	–	373
2020 Q4	$1K	Buy	+63	New	+$606	﹤0.01%	737

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Inspire Advisors's IBRX Position: Q1 2021 in Review

Inspire Advisors sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 63 shares — an estimated $1K sold.

Inspire Advisors first reported a position in IBRX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

Inspire Advisors reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 63 ImmunityBio shares in Q1 2021, an estimated $1K.
Inspire Advisors first reported a position in ImmunityBio in Q4 2020 and held it in 1 quarter.
Inspire Advisors's ImmunityBio position peaked at $1K in Q4 2020.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.